Lv21
158 积分 2026-01-18 加入
Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis
1个月前
已完结
Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and MAIC
1个月前
已完结
Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis
1个月前
已完结
Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability
2个月前
已完结
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
2个月前
已完结
Bimekizumab versus Secukinumab in Plaque Psoriasis
2个月前
已完结
Bimekizumab versus Adalimumab in Plaque Psoriasis
2个月前
已完结
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
2个月前
已完结
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
2个月前
已完结
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)
2个月前
已完结
皖公网安备34019202002308
